Evidence map›Paper›PMID 42311431›Full record

ArticleHemaSphere2026

Distinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman-Diamond syndrome.

Laura Langohr, Ilse Kaaja, Suvi P M Douglas, Hanna Nebelung, Jessica Koski, Ina Ikonen, Lotta Katainen, Katri Maljanen, Marja Hakkarainen, Tuulia Räisänen and 10 more

Abstract read
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Laura LangohrApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0003-0493-5551
Ilse KaajaApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0009-0001-0415-8679
Suvi P M DouglasApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0003-4412-688X
Hanna NebelungApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0009-0005-8901-1674
Jessica KoskiApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0003-3619-652X
Ina IkonenApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.
Lotta KatainenApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.
Katri MaljanenApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0009-0003-4547-0233
Marja HakkarainenApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0003-3793-4803
Tuulia RäisänenApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0009-0005-9947-498X
Riitta NiinimäkiDepartment of Pediatrics, Oulu University Hospital and PEDEGO Research Unit University of Oulu Oulu Finland.
Sakari KakkoCancer Center, Oulu University Hospital Oulu Finland.
Timo SiitonenCancer Center, Oulu University Hospital Oulu Finland.
Sadiksha AdhikariInstitute for Molecular Medicine Finland (FIMM), HiLIFE University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0002-7471-014X
Markus Vähä-KoskelaInstitute for Molecular Medicine Finland (FIMM), HiLIFE University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0001-7764-7820
Caroline A HeckmanInstitute for Molecular Medicine Finland (FIMM), HiLIFE University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0002-4324-8706
Jenni LahtelaInstitute for Molecular Medicine Finland (FIMM), HiLIFE University of Helsinki Helsinki Finland.
Ulla Wartiovaara-KauttoApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0002-2803-2712
Esa PitkänenInstitute for Molecular Medicine Finland (FIMM), HiLIFE University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0002-9818-6370
Outi KilpivaaraApplied Tumor Genomics Research Program, Research Programs Unit, Faculty of Medicine University of Helsinki Helsinki Finland.ORCID https://orcid.org/0000-0001-8467-2100

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ERCC6L2 disease (ED) is a rare bone marrow failure syndrome caused by biallelic germline mutations in

Identifiers

PMID42311431
PMCPMC13270343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.